Sanofi announced today that the U.S. FDA has granted orphan drug designation to rilzabrutinib for the treatment of sickle ...

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease <li /> Fourth orphan drug designation for rilzabrutinib ...